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Abstract 
 
Darier Disease (DD) is an autosomal dominant skin disorder caused by mutations in 
ATP2A2 encoding the sarco/endoplasmic reticulum Ca2+ ATPase isoform 2 (SERCA2). 
Evidence of a population-level association between DD and psychiatric disorders 
suggests that mutations in ATP2A2 may have pleiotropic effects on the brain as well as 
skin. Evidence of genotype-phenotype relationships between ATP2A2 mutations and 
neuropsychiatric phenotypes would further support this suggestion.    
We investigated genotype-phenotype correlations between lifetime neuropsychiatric 
features and ATP2A2 mutation type (dichotomized into likely gene disrupting (LGD) or 
protein altering (PA)) in 75 unrelated individuals with DD. We also looked for evidence 
of clustering of mutations within SERCA2 according to neuropsychiatric features. 
Combining our data with the existing literature, the rate of LGD mutations was found 
to be significantly higher among DD cases/families with bipolar disorder, schizophrenia 
or affective psychosis (p=0.011). We also found a significant relationship between 
mutations located in the S4-M4 region of the protein and the presence of a severe 
neuropsychiatric phenotype (p=0.032). 
Our findings add support to the hypothesis that Darier-causing mutations in ATP2A2 
confer susceptibility to neuropsychiatric dysfunction, in particular severe psychiatric 
illness. This, together with evidence from research on common polymorphisms confirms 
ATP2A2 as a gene at which variation influences susceptibility to major psychiatric illness. 
(word count n=206) 
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1. INTRODUCTION 
Darier disease (DD) is a rare autosomal dominant inherited skin disorder with an 
estimated average prevalence of between 1 in 100,000 to 30,000 (Svendsen & Albrectsen, 
1959; Tavadia, Mortimer, & Munro, 2002) and usually presents in the second decade with 
no sex difference (Burge & Wilkinson, 1992). It is characterised by hyperkeratotic 
papules in seborrheic areas, palmo-plantar pits and nail dystrophy. DD is inherited with a 
high penetrance although the phenotypic expression is variable (Munro, 1992). 
 
The disease is caused by mutations in the gene ATP2A2 (Sakuntabhai, Ruiz-Perez, et al., 
1999) which encodes the sarco/endoplasmic reticulum Ca2+ ATPase isoform 2 
(SERCA2), a calcium pump located in the endoplasmic reticulum (ER) membrane which 
plays a key role in Ca2+ homeostasis. The protein contains five major domains which 
include 11 transmembrane helices (M1-M11), 5 stalks (S1-S5) and three cytoplasmic 
domains; the actuator (A) domain, the nucleotide ATP-binding (N) domain and the 
phosphorylation (P) domain. To date well over 200 different Darier-causing mutations 
have been identified throughout ATP2A2 including missense, nonsense, substitutions, and 
both frame-shift and in-frame insertions and deletions (Human Gene Mutation Database 
http://www.hgmd.org). Generally, these mutations do not seem to cluster within potential 
‘hot-spot’ regions throughout the primary sequence of the SERCAb molecule and most 
are unique within individual families.  
 
The co-occurrence of neuropsychiatric features, including depression, bipolar disorder, 
epilepsy and learning difficulties, with DD has frequently been reported (Burge & 
Wilkinson, 1992; Cederlöf, Bergen, et al., 2015; Cederlöf, Karlsson, et al., 2015; 
Denicoff, Lehman, Rubinow, Schmidt, & Peck, 1990; Dodiuk-Gad et al., 2014, 2016; 
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Gordon-Smith et al., 2010; Medansky & Woloshin, 1961; Ringpfeil et al., 2001). The 
nature of this co-occurrence has long been debated in the literature with a number of 
potential explanations being put forward. A seemingly plausible explanation is that the 
high psychiatric morbidity observed in DD is a direct psychological consequence of 
having a chronic skin disorder. However, our previous investigations into the 
neuropsychiatric phenotype in DD and the work of others have not found any significant 
relationships between psychiatric phenotypes and DD clinical features including disease 
severity suggesting this argument alone cannot account for the association (Dodiuk-Gad 
et al., 2016; Gordon-Smith et al., 2010).        
 
In recent years, studies have found evidence of a population-level association between 
DD and psychiatric disorders - specifically mood disorders, including bipolar disorder, 
and schizophrenia (Cederlöf, Bergen, et al., 2015; Dodiuk-Gad et al., 2016; Gordon-
Smith et al., 2010). This included a matched cohort study based on Swedish national 
registers that found individuals with DD had a 4.3 and 2.3 times higher risk of bipolar 
disorder and schizophrenia respectively than individuals in the general population 
(Cederlöf, Bergen, et al., 2015). These findings suggest that mutations in ATP2A2 have 
pleiotropic effects in the skin and brain and confer susceptibility to neuropsychiatric 
features. This theory would be strongly supported by evidence of genotype-phenotype 
relationships between ATP2A2 mutation type and co-occurrence of neuropsychiatric 
phenotypes.    
 
To date, a small number of studies have examined genotype-phenotype correlations with 
the neuropsychiatric phenotypes observed in DD (Bchetnia et al., 2009; Dodiuk-Gad et 
al., 2016; Jacobsen et al., 1999; Nellen et al., 2016; Ringpfeil et al., 2001; Ruiz-Perez et 
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al., 1999; Sakuntabhai, Burge, Monk, & Hovnanian, 1999) with no clear and consistent 
correlations being identified. Difficulties in establishing these relationships may be due to 
a number of reasons including small sample sizes (ranging from 8-49 cases) and the use 
of diverse methods to measure neuropsychiatric phenotypes. The lack of consistent 
application of any standardized method of grouping the types of mutations has also been a 
major methodological impediment. A recent review of the literature divided reported 
Darier-causing mutations into two categories: (a) likely gene disrupting (LGD) mutations 
(frameshift, splice site, nonsense, gain of stop codon or loss of start codon) and (b) 
protein altering (PA) mutations (missense or inframe-insertion/deletions) (Nakamura et 
al., 2016). This study found significantly higher rates of LGD mutations in Darier cases 
with reported co-occurring neuropsychiatric features than in those without such features. 
A single study has reported a non-random clustering of mutations in the last half of 
ATP2A2 and a neuropsychiatric phenotype (in a sample of 19 unrelated individuals with 
DD) (Jacobsen et al., 1999). However no other genotype-phenotype associations between 
mutation location along the primary structure of the gene and the presence of 
neuropsychiatric features have been reported in other samples (Dodiuk-Gad et al., 2016; 
Nellen et al., 2016; Ringpfeil et al., 2001) including the recent literature survey 
(Nakamura et al., 2016). The authors of the survey noted that this lack of association 
would be reasonable as LGD mutations in any exon could result in similar molecular 
consequences.  
 
We have previously reported a systematic investigation of the neuropsychiatric 
characteristics in a large UK sample of unrelated individuals with DD (Gordon-Smith et 
al., 2010) and more recently reported the disease causing sequence variants of ATP2A2 
within this large sample (Green et al., 2013). Although these mutations were included in 
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the recent analysis by Nakamura et al. (2016) the associated neuropsychiatric phenotypes 
were unknown to the authors at the time.  In the current study we investigated potential 
correlations between mutation type (LGD vs PA) and neuropsychiatric phenotypes among 
75 unrelated individuals with DD. This is the largest such study to date. This large sample 
has also enabled us to look for evidence of clustering of mutations within the SERCA2 
protein among individuals with similar neuropsychiatric phenotypes and we report that 
here. Using this clustering approach may be a more useful way of examining genotype-
phenotype correlations with neuropsychiatric phenotypes in DD given the likely complex 
nature of the associations. Finally we combined our sample with previously reported DD 
cases/families in the literature to date to establish whether any genotype-phenotype 
correlations observed were enriched in the combined dataset.  
 
2. MATERIALS AND METHODS 
 
2.1 Recruitment of participants 
A detailed description of the sample has previously been published (Gordon-Smith et al., 
2010).  In summary, 100 unrelated individuals with a diagnosis of DD were recruited 
throughout the United Kingdom mainly via dermatology services and the U.K. Darier 
Support Group. The study was approved by the Multi-Centre Research Ethics Committee 
for Wales (MREC). 
 
2.2 Neuropsychiatric assessment 
Neuropsychiatric assessments were conducted in a single session by a trained research 
psychologist (KGS). Psychiatric symptomatology, including history of suicidal 
thoughts/attempts, was measured using an adapted version of Schedules for Clinical 
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Assessment in Neuropsychiatry interview (Wing et al., 1990). This information was 
supplemented by psychiatric notes and/or general practice case-notes. Lifetime-ever 
psychiatric diagnoses were made according to the Diagnostic and Statistical Manual of 
Mental Disorders, Fourth Edition, (DSM-IV) (American Psychiatric Association, 2000). 
Three experienced research psychologists/psychiatrists (KGS, LJ, NC) made the 
psychiatric ratings independently, using written case vignettes, and consensus was 
reached. Inter-rater reliability was high with mean kappa statistics of 0.86 and 0.93 for 
DSM-IV diagnoses and suicidal ideation respectively. Lifetime history of neurological 
symptoms and disorders was assessed using a brief interview checklist, supplemented by 
hospital and/or general practice case-notes. 
 
 
2.3 ATP2A2 variant identification 
A DNA sample was obtained from 95 individuals. 66 potentially pathogenic mutations in 
ATP2A2 were identified in 74 individuals. No potentially pathogenic variant in ATP2A2 
was identified in the remaining 21 individuals. One of the five remaining individuals from 
whom a sample was not collected had taken part in a previous study (Sakuntabhai, Ruiz-
Perez, et al., 1999) from which the potential pathogenic variant was supplied. For further 
details on the identification of mutations see our previous publication (Green et al., 2013).  
 
2.4 Genotype-phenotype correlations 
According to the definitions used in a recent study (Nakamura et al., 2016) mutations 
were classified as either likely gene disrupting (LGD) (frameshift insertions/deletions, 
mutations predicted to alter a splice codon, nonsense mutations, gain of stop codon or loss 
of start codon) or protein altering (PA) (missense or inframe-insertion/deletions).  
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Rates of LGD and PA mutations were compared between individuals stratified according 
to the presence or absence of each of the following key lifetime neuropsychiatric features: 
i) any neuropsychiatric phenotype,  
ii) any psychiatric disorder meeting DSM-IV criteria, 
iii) contact with a neurologist or neurological procedure, 
iv) suicide attempt, 
v) severe neuropsychiatric phenotype (bipolar disorder, schizophrenia or 
affective psychosis).  
 
All mutations detected were mapped onto a schematic diagram of the SERCA2b protein 
to look for evidence of possible clustering of mutations according to occurrence within 
individuals of similar neuropsychiatric features. 
 
2.5 Combined analysis with existing literature 
We combined our sample with the previously reported DD cases/families in the literature 
with an identified Darier causing mutation (n=384 including the current sample).  
Within the combined sample we  
1) Compared rates of LGD and PA mutations according to the absence or 
presence of a reported severe neuropsychiatric phenotype 
2) Compared the rates of mutations located in specific functional domains of the 
SERCA2 protein according to the absence or presence of a reported severe 
neuropsychiatric phenotype 
A severe neuropsychiatric phenotype was rated as present if the index case and/or a 
family member with DD was reported as having a diagnosis of bipolar disorder, 
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schizophrenia or affective psychosis. All members of the same family will have the same 
DD causing mutation and therefore a shared diathesis. Within this analysis we also 
included an unpublished missense mutation (P312R) identified in an individual with DD 
and bipolar disorder seen by our research group as part of our ongoing mood disorders 
research programme who was not included in the current study as they were identified on 
the basis of having bipolar disorder rather than on the basis of having DD.   
 
2.6 Statistical analyses 
Groups were compared using chi-square tests or Fisher’s exact tests where 20% or more 
of the cells in a chi-square table had an expected count of <5. For significant findings 
(p<0.05) odds ratios with 95% confidence intervals were calculated. Statistical analyses 
were carried out using SPSS for Windows. 
 
3. RESULTS 
3.1 Current sample (75 cases) 
Table 1 summarises the DD clinical and neuropsychiatric features in the sample along 
with the type and location of ATP2A2 mutation identified and mutation classification 
according to the LGD and PA groupings. 
 
In our 75 cases we found a consistent non-significant trend for a higher prevalence of 
LGD mutations among individuals with a lifetime occurrence of each of the 
neuropsychiatric phenotypes compared with individuals with the absence of the 
neuropsychiatric phenotype (any neuropsychiatric phenotype 45.5% vs. 35%, p=0.418; 
any psychiatric disorder meeting DSM-IV criteria 46% vs. 38%, p=0.480; contact with a 
neurologist or neurological procedure 53% vs 36%, p=0.127; suicide attempt 50% vs. 
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41%, p=0.733; severe neuropsychiatric phenotype 75% vs. 41%, p=0.307). (Figure 1 and 
Table 2). 
 
We observed possible clustering of mutations according to individuals with similar 
neuropsychiatric phenotypes (Figure 2) but none reached statistical significance: 
 All four individuals with mutations located in the functional ‘A’ domain between 
the stalk 2 and stalk 3 domains of the protein had a history of a psychiatric 
disorder severe enough to warrant contact with psychiatric services (IDs 11, 12, 
13 & 14). 
 Three individuals with the same missense mutation at one of the seven Ca2+ 
binding sites in the M5 domain all had a DSM-IV diagnosis of a mood disorder 
(ID 54, 55, & 56). 
 Two individuals with frameshift mutations one base pair apart in the S4 (Stalk 4) 
domain of the protein both had a history of suicide attempts in addition to having 
idiopathic epilepsy (ID 19) and an extensive psychiatric history including major 
depressive disorder and investigations for a blackout (ID 20). 
 
3.2 Analysis of combined data with existing literature (384 cases) 
In the combined analysis with existing literature, the rate of LGD mutations was 
significantly higher where a history of a severe neuropsychiatric phenotype (bipolar 
disorder, schizophrenia or affective psychosis) was reported in either the index case 
and/or family member with DD compared those without a reported history; 68% vs. 
40.5%, p=0.011 (OR 3.15, 95% CI 1.25-7.91) (Table 3). This remained significant when 
we only included the 14 cases of bipolar disorder; 71.4% vs. 41.0%, p=0.024 (OR 3.44, 
95% CI 1.10-10.76). With respect to mutation location, no significant genotype-
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phenotype correlations were found with mutations located in the ‘A’ domain of the 
SERCA2 protein or calcium binding sites. However, the rate of mutations located 
between the stalk 4 and transmembrane helix 4 (S4-M4) region was significantly higher 
where a history of a severe neuropsychiatric phenotype was reported compared to where 
not; 14% vs. 3%, Fisher’s=0.032 (OR 5.66, 95% CI 1.41-21.88).  When this analysis was 
narrowed down further to only include PA, mutations this became more significant: 43% 
vs. 4%, Fisher’s=0.003 (OR 19.22, 95% CI 3.67-100.6).  A summary of all mutations 
identified by our research group and those in the literature located within the S4-M4 
region is presented in Figure 3 along with brief descriptions of all known 
neuropsychiatric features reported among individuals/families with DD the mutations. 
This includes two families with bipolar disorder and an individual with schizophrenia 
(Figure 3). 
 
4. DISCUSSION 
Our genotype-phenotype investigations have been carried out in the largest sample of 
individuals with DD to date.  Consistent with the recent prior report (Nakamura et al., 
2016), we found that LGD mutations were relatively more common in those DD 
individuals with neuropsychiatric phenotypes than those without such phenotypes. We 
had only four cases in our sample that met the prior report’s definition of ‘psychosis’ 
(bipolar disorder, schizophrenia and affective psychosis). Of these four cases, three had 
LGD mutations and one had a PA mutation. Because of the small numbers, this difference 
compared to those with DD without ‘psychosis’ does not meet statistical significance. 
However, when we add our new data to the existing literature the statistical significance 
of the finding that the rate of LGD mutations is higher among cases/families with this 
severely defined neuropsychiatric phenotype is strengthened (p=0.011, compared with the 
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previously reported p=0.026 (Nakamura et al., 2016) which although included our cases 
the neuropsychiatric features associated with the mutations were unknown to the authors), 
and this association remains significant even when the phenotype definition is narrowed 
to include only bipolar disorder. We also observed in our sample that mutations in 
individuals with similar neuropsychiatric phenotypes tended to cluster in certain locations 
within the SERCA2 protein but none reached statistical significance. In our combined 
analysis we did however find a significant relationship with mutations located in the S4-
M4 region of the protein and the presence of a severe neuropsychiatric phenotype. 
Furthermore when this analysis was repeated with only PA mutations the association 
remained significant. This finding has not previously been reported.  
 
It is highly plausible that mutations in ATP2A2 could be involved in conferring 
susceptibility to neuropsychiatric illness since the gene is widely expressed in the brain.  
The dual role of the SERCA2b protein in intracellular Ca2+ signaling and in the synthesis 
and post-translational modification of proteins within the endoplasmic reticulum (ER) 
also provides support for this suggestion. Intracellular Ca2+ signaling has been shown to 
play a role in a range of neuronal functions including neuronal excitability, 
neurotransmitter release, gene expression, neuronal growth and synaptic plasticity 
(Berridge, 2002; Berridge, Bootman, & Lipp, 1998; Verkhratsky, 2005). Genome-wide 
association studies (GWAS) have suggested the role of calcium signaling and calcium-
channel activity in the pathogenesis of a number of major psychiatric disorders, including 
bipolar disorder and schizophrenia (Cross-Disorder Group of the Psychiatric Genomics 
Consortium & Genetic Risk Outcome of Psychosis (GROUP) Consortium, 2013; Ferreira 
et al., 2008) with a more recent GWAS identifying ATP2A2 as a schizophrenia-associated 
loci (Ripke et al., 2014).  
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A recent study showing Darier keratinocytes display the hallmarks of constitutive ER 
stress with increased sensitivity to ER stressors lead the authors of the study to suggest 
DD should be classed as an ER stress related disease (Savignac, Simon, Edir, Guibbal, & 
Hovnanian, 2014). There is also evidence for the role of ER stress responses in 
neuropsychiatric disorders. Lymphoblastoid cell lines from individuals with bipolar 
disorder have showed an impaired response to ER stress (Hayashi et al., 2009; 
Pfaffenseller et al., 2014; So, Warsh, & Li, 2007). Lithium is the main mood stabiliser 
used in the treatment of bipolar disorder and a recent study identified the response to ER 
stress as a lithium-regulated gene network (Breen et al., 2016). It is possible that the 
function of SERCA2b pumps may be more critical in the skin and the brain than in other 
tissues. Both tissues may have a particular susceptibility to a reduction in SERCA2b 
activity possibly relating to changes in ER Ca2+ concentration and ER functioning. 
 
A limitation of the current analysis is that despite being the largest study to date, the small 
stratified group sizes in our genotype-phenotype analyses limits the power to detect 
significant relationships. Combining our sample with the existing literature enabled us to 
address this. However, previous studies of DD cases/families in the literature have not all 
recorded and/or reported neuropsychiatric features. Similarly, where neuropsychiatric 
features have been reported previously in the literature, in many cases only brief 
descriptions are provided.  Ours and other studies have not included detailed assessments 
of the presence of neurological features such as hearing difficulties. Further studies 
systematically assessing neuropsychiatric features in individuals with DD are warranted 
including the administration of specific neurological tests such as audiograms. 
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We have found evidence to support the suggestion that mutations in ATP2A2 in addition 
to causing DD, confer susceptibility to neuropsychiatric features in individuals with DD. 
Given the complex nature of the disorders it is likely that the pleiotropic effects occur in 
association with other modifying factors. Our findings suggest that DD causing mutations 
as well as other genes encoding proteins in the same biological system as, and/or 
encoding proteins with a similar function to, SERCA2b would be good candidates for 
further investigations of potential involvement in predisposing individuals to developing 
severe neuropsychiatric illness. 
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Table 1 Clinical and neuropsychiatric features in 75 individuals with Darier Disease and type and location of ATP2A2 mutations 
ID Sex Severity of DD Neuropsychiatric phenotype Location Nucleotide and alteration Amino acid alteration Type Protein domain 
LGD or 
PA 
mutation 
1 F Moderate  Exon 1 1A>G Met1V Missense Start codon LGD 
2 M Moderate  Exon 1 34+57ins 
V29Met ins repeat of 
previous 19 amino acids 
In-frame insertion A domain 
PA 
3 M Moderate 
Investigations for hearing 
problems. 
Exon 1 48 del14 / ins11 V18X Frameshift (PTC +1aa) A domain 
LGD 
4 M Mild  Exon 1 94C>T L32F Missense A domain PA 
5 M Mild Epilepsy. Intron 2 137-3C>G  Splice site  LGD 
6 F Moderate 
Bipolar I disordera. Investigations 
for periods of unconsciousness. 
Exon 3 142  Ins 18  Frameshift (PTC+14aa) S1 
LGD 
7 F Mild Major depressive disorder
a. Exon 3 167A>G Q56R Missense M1 PA 
8 F Severe Major depressive disorder. Exon 3 194T>C L65S Missense M1 PA 
9 F Moderate Dysthymic disorder. Intron 3 219+5 insAA  Splice site  LGD 
10 M Moderate 
Investigations for hearing 
problems. 
Intron 5 325-2A>G  Splice site M2 
LGD 
11 F Moderate Bipolar I disordera. Intron 6 464-1A>C  Splice site A domain LGD 
12 F Moderate Major depressive disordera. Exon 6 490A>G R164G Missense A domain PA 
13 F Moderate Major depressive disordera. Exon 6 543delA  Frameshift (PTC+42aa) A domain LGD 
14 M Moderate 
Depression NOSa. Suicide 
attempt. 
Exon 8 698G>T G233V Missense A domain 
PA 
15 F Moderate  Exon 8 826 del 15 Del 276-300 (IGHFN) In-frame deletion M3-M4 lumenal PA 
16 F Severe Depression NOS. Exon 8 923C>A P308H Missense M4 PA 
17 M Moderate Treatment for hearing problems. Exon 8 925G>A E309K Missense M4 PA 
18 F Severe  Exon 8 929G>T G310V Missense M4 PA 
19 F Moderate 
Psychiatric disorder NOSa. 
Suicide attempt. Epilepsy. 
Exon 8 948delC  Frameshift (PTC+65aa) S4 
LGD 
20 F Moderate 
Major depressive disordera. 
Suicide attempt. Investigations for 
a blackout. 
Exon 8 949del7  Frameshift (PTC+65aa) S4 
LGD 
21 F Mild  Exon 8 958 G>C A320P Missense S4 PA 
22 F Moderate Headaches requiring investigation. Exon 8 1000C>T R334X Nonsense P domain LGD 
23 M Severe  Exon 8 1000C>T R334X Nonsense P domain LGD 
24 M Severe  Exon 8 1043T>C I348T Missense P domain PA 
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Table 1 Clinical and neuropsychiatric features in 75 individuals with Darier Disease and type and location of ATP2A2 mutations 
ID Sex Severity of DD Neuropsychiatric phenotype Location Nucleotide and alteration Amino acid alteration Type Protein domain 
LGD or 
PA 
mutation 
25 F Mild  Exon 8 1070C>G T357R Missense P domain PA 
26 M Moderate 
Major depressive disorder. 
Investigations for hearing 
problems. 
Exon 8 1070C>A T357K Missense P domain 
PA 
27 F Moderate 
Major depressive disorder. 
Investigations for suspected 
epileptic seizure. 
Exon 8 1095+1G>C  Splice site P domain 
LGD 
28 F Moderate 
Major depressive disordera. 
Suicide attempt. Headaches 
requiring investigation. 
Exon/  
Intron 10 
1228 del 86  Deletion N domain 
LGD 
29 M Moderate 
Investigations for fainting 
episodes. 
Exon 11 1321A>C T441P Missense N domain 
PA 
30 F Moderate 
Major depressive disordera. 
Multiple suicide attempts. 
Investigations for blackouts. 
Exon 11 1413C>A C471X Nonsense N domain 
LGD 
31 F Moderate 
Investigations for fainting 
episodes. 
Exon 11 1419 del GA  Frameshift (PTC+1aa) N domain 
LGD 
32 F Moderate Major depressive disorder. Exon 12 1484C>T S495L Missense N domain PA 
33 F Mild 
Major depressive disorder. Suicide 
attempt. 
Exon 12 1484C>T S495L Missense N domain 
PA 
34 F Mild Panic disorder. Exon 12 1508del C  Frameshift (PTC+5aa) N domain LGD 
35 F Mild Treatment for viral encephalitis. Exon 13 1628_1630delAGA del K543 In-frame deletion N domain PA 
36 F Moderate 
Bipolar I disordera. Suicide 
attempt. Investigations following 
an episode of loss of 
consciousness. 
Exon 13 1697dupA  Frameshift (PTC+1aa) N domain 
LGD 
37 F Moderate Major depressive disorder
a. Exon 13 1713delAA  Frameshift (PTC+4aa) N domain LGD 
38 M Mild  Intron 13 1762-1G>C  Splice site N domain LGD 
39 M Mild  Exon 14 1919InsT  Frameshift (PTC+4aa) P domain LGD 
40 F Moderate 
Major depressive disorder. 
Investigations for fainting 
episodes. 
Exon 14 2017del C  Frameshift (PTC+14aa) P domain 
LGD 
41 M Moderate Anxiety disorder NOS. Exon 14 2046 Ins C  Frameshift (PTC+2aa) P domain LGD 
42 F Moderate Investigations for blackouts. Exon 14 2048A>T K683M Missense P domain PA 
43 F Moderate  Intron 14 2098-2A>C  Splice site P domain LGD 
44 F Moderate 
Dysthymic disordera. 
Investigations for headaches. 
Exon 15 2104G>A D702N Missense P domain 
PA 
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Table 1 Clinical and neuropsychiatric features in 75 individuals with Darier Disease and type and location of ATP2A2 mutations 
ID Sex Severity of DD Neuropsychiatric phenotype Location Nucleotide and alteration Amino acid alteration Type Protein domain 
LGD or 
PA 
mutation 
45 M Moderate 
Major depressive disordera. 
Suicide attempt. 
Exon 15 2116G>A D706N Missense P domain 
PA 
46 M Moderate  Exon 15 2116G>A D706N Missense P domain PA 
47 F Moderate 
Investigations for hearing 
problems. 
Exon15 2123C>A P708H Missense P domain 
PA 
48 M Moderate Major depressive disorder. Exon 15 2249G>A R750Q Missense S5 PA 
49b F Moderate  Exon 15 2258del3bp  In-frame deletion S5 PA 
50 M Moderate Depression NOS. Exon 15 2287C>G L763V Missense S5 PA 
51 M Moderate  Exon 15 2294C>T S765L Missense M5 PA 
52 M Moderate 
Investigations for loss of feeling 
in lower limbs. 
Exon 15 2294C>T S765L Missense M5 
PA 
53 M Moderate 
Treatment for hearing problems. 
Investigations for poor memory. 
Exon 15 2300A>G N767S Missense M5 
PA 
54 F Moderate 
Major depressive disordera. 
Investigations for blackouts. 
Exon 15 2300A>G N767S Missense M5 
PA 
55 F Moderate 
Major depressive disorder. 
Investigations for hearing 
problems. 
Exon 15 2300A>G N767S Missense M5 
PA 
56 F Mild 
Depression NOS. Investigations 
for hearing problems. 
Exon 15 2300A>G N767S Missense M5 
PA 
57 M Mild  Exon 15 2317T>C C773R Missense M5 PA 
58 F Moderate 
Depression NOS. Investigations 
for headache and fainting 
episodes. 
Intron 15 2319-1G>A  Splice site  
LGD 
59 F Moderate Anxiety disorder NOS. Exon 16 2384A>G N795S Missense M6 PA 
60 F Moderate Bipolar I disordera. Exon 16 2405C>G P802R Missense M6 PA 
61 F Moderate Major depressive disorder. Exon 16 2417T>G L806R Missense M6 PA 
62 F Severe 
Major depressive disordera. 
Suicide attempt. Investigations for 
blackouts. 
Exon 17 2527G>T V843F Missense M7 
PA 
63 M Moderate  Exon 17 2584InsG  Frameshift (PTC+14aa) M7-M8 lumenal LGD 
64 F Moderate Major depressive disorder
a. Exon 18 2620C>T Q874X Nonsense M7-M8 lumenal LGD 
65 F Mild Major depressive disorder. Exon 18 2678dupC  Frameshift (PTC+16aa) M7-M8 lumenal LGD 
66 M Moderate Depression NOS. Suicide attempt. Exon 18 2684C>T P895L Missense M7-M8 lumenal PA 
67 F Moderate  Exon18 2709 del 6bp del V904 & T905 In-frame deletion M8 PA 
68 F Moderate Depression NOS. Exon 18 2730 Ins C  Frameshift (PTC+71aa) M8 LGD 
69 F Moderate  Exon 18 2741+1G>T  Splice site  LGD 
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Table 1 Clinical and neuropsychiatric features in 75 individuals with Darier Disease and type and location of ATP2A2 mutations 
ID Sex Severity of DD Neuropsychiatric phenotype Location Nucleotide and alteration Amino acid alteration Type Protein domain 
LGD or 
PA 
mutation 
70 F Severe 
Major depressive disorder. 
Investigations for blackouts. 
Exon 18 2741+5G>C  Splice site  
LGD 
71 F Moderate 
Depression NOS. 
Exon 19 2759C>T S920F Missense 
M8-M9 
Cytoplasmic 
PA 
72 F Severe 
Investigations for one-sided 
weakness. 
Exon 19 2759C>A S920Y Missense 
M8-M9 
Cytoplasmic 
PA 
73 M Severe 
Medical notes report "adjustment 
reaction” to relapse in DDa,c. 
Exon 19 2759C>A S920Y Missense 
M8-M9 
Cytoplasmic 
PA 
74 F Mild 
Cyclothymic disordera. 
Exon 19 2777C>G P926R Missense 
M8-M9 
Cytoplasmic 
PA 
75 F Moderate 
Treatment for meningitis 
(unknown type). 
Exon 20a 2965del 7 Ins 9 & 2983del A  Frameshift (PTC+42aa) 
M10-M11 
Cytoplasmic 
LGD 
a Requiring contact with psychiatric services, b mutation identified in previous study(Sakuntabhai, Ruiz-Perez, et al., 1999), c Classified as a maladjustment reaction as the patient was referred 
and seen by secondary psychiatric services,  LGD = likely gene disrupting, PA = protein-altering, NOS = not otherwise specified, Sn= stalk domains, Mn; transmembrane domains, A 
domain= actuator domain, N domain= nucleotide binding, P domain= phosphorylation domain. 
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Table 2 Likely gene-disrupting (LGD) and protein-altering (PA) mutations among 75 individuals with and without the lifetime occurrence of neuropsychiatric phenotypes  
 Any neuropsychiatric 
phenotype 
Any psychiatric disorder Neurologist or 
neurological procedure 
Suicide attempt Severe neuropsychiatric 
phenotype  
 Yes No Yes No Yes No Yes No Yes No 
 N % N % N % N % N % N % N % N % N % N % 
LGD 25 45.5 7 35 19 46 13 38 16 53 16 36 5 50 25 41 3 75 29 41 
PA 30 54.5 13 65 22 54 21 62 14 47 29 64 5 50 36 59 1 25 42 59 
Total N* 55 20 41 34 30 45 10 61 6 69 
 χ2 =0.655,df=1, p= 0.418 χ2 =0.499, df=1, p= 0.480 χ2 =2.326, df=1, p= 0.127 Fisher’s, p=0.733 Fisher’s p=0.307            
*Ns vary due to unknown data 
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Table 3 Combined analysis with previously reported cases/families in the literature (n=384):  comparison of mutation type and location according to the absence or presence 
of a reported severe neuropsychiatric phenotype (bipolar disorder, schizophrenia or affective psychosis) 
 
 Reported severe neuropsychiatric phenotype in index case and/or 
family member with DD 
 
 Yes (n=22) No (n=362)  
Likely gene-disrupting (LGD) mutation    
Yes n (%) 15 (68) 145 (40.5) χ2 =6.514,df=1, p= 0.011 
OR 3.15, 95% CI 1.25-7.91 No n (%) 7 (32) 213 (59.5) 
    
Mutation located in actuator ‘A’ domain     
Yes n (%) 1 (4.5) 73 (20) Fisher’s, p= 0.093 
No n (%) 21 (95.5) 289 (80)  
    
Mutation located at calcium binding site    
Yes n (%) 2 (9) 18 (5) Fisher’s, p= 0.320 
No n (%) 20 (91) 344( 95)  
    
Mutation located between stalk 4 and 
transmembrane helix 4 (S4-M4)  
  
 
Yes n (%) 3 (14) 10 (3) Fisher’s, p= 0.032 
OR 5.66, 95% CI 1.41-21.88 No n (%) 19 (86) 352 (97) 
    
Mutation located between stalk 4 and 
transmembrane helix 4 (S4-M4) . 
Protein altering mutations only 
Yes (n=7) No (n=213)  
Yes n (%) 
3 (43) 8 (4) 
Fisher’s, p= 0.003 
OR 19.22, 95% CI 3.67-100.6 
No n (%) 4 (57) 205 (96)  
    
DD= Darier disease, OR=odds ratio, CI=confidence interval. Ns vary due to four mutations in the literature that could not be classified according to type due to unknown 
function. 
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FIGURE 1 Comparison of prevalence of likely gene-disrupting (LGD) and protein-altering (PA) mutations among 75 individuals with 
and without the lifetime occurrence of neuropsychiatric phenotypes  
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FIGURE 2 Key observations of evidence for possible clustering of mutations within the SERCA2b protein among 75 individuals with 
similar neuropsychiatric phenotypes 
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FIGURE 3 All known neuropsychiatric features in individuals/families with Darier disease causing mutations in the S4-M4 domain of 
SERCA2 including cases in current study 
ER= Endoplasmic reticulum, S=stalk domain, M=transmembrane domain, NOS=not otherwise specified. Mutations have been found to be 
unique to families, except for mutations marked 2 where mutations have been reported in two unrelated families.   
 a Unpublished mutation identified in an individual with DD seen by our research group who was not included in the current study.   
 b Parent of index was admitted to psychiatric hospital with ‘high mood’ although neither parent was reported to have DD.  
All mutations are located in Exon 8. 
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